Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Advanced Non-Squamous NSCLC
NCT00354549Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jan 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and erlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Jan 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00354549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354549.